tetano
Editor, Senior Moderator
J Clin Microbiol
. 2021 Nov 3;JCM0165921.
doi: 10.1128/JCM.01659-21. Online ahead of print.
Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: an IDSA/ASM Consensus Review Document
Alexander L Greninger[SUP] 1 [/SUP], Jennifer Dien Bard[SUP] 2 [/SUP], Robert C Colgrove[SUP] 3 [/SUP], Erin H Graf[SUP] 4 [/SUP], Kimberly E Hanson[SUP] 5 [/SUP], Mary K Hayden[SUP] 6 [/SUP], Romney M Humphries[SUP] 7 [/SUP], Christopher F Lowe[SUP] 8 [/SUP], Melissa B Miller[SUP] 9 [/SUP], Dylan R Pillai[SUP] 10 [/SUP], Daniel D Rhoads[SUP] 11 [/SUP], Joseph D Yao[SUP] 12 [/SUP], Francesca M Lee[SUP] 13 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.
. 2021 Nov 3;JCM0165921.
doi: 10.1128/JCM.01659-21. Online ahead of print.
Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: an IDSA/ASM Consensus Review Document
Alexander L Greninger[SUP] 1 [/SUP], Jennifer Dien Bard[SUP] 2 [/SUP], Robert C Colgrove[SUP] 3 [/SUP], Erin H Graf[SUP] 4 [/SUP], Kimberly E Hanson[SUP] 5 [/SUP], Mary K Hayden[SUP] 6 [/SUP], Romney M Humphries[SUP] 7 [/SUP], Christopher F Lowe[SUP] 8 [/SUP], Melissa B Miller[SUP] 9 [/SUP], Dylan R Pillai[SUP] 10 [/SUP], Daniel D Rhoads[SUP] 11 [/SUP], Joseph D Yao[SUP] 12 [/SUP], Francesca M Lee[SUP] 13 [/SUP]
Affiliations
- PMID: 34731022
- DOI: 10.1128/JCM.01659-21
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.